tiprankstipranks
Annovis Bio Shares Surge on Positive Parkinson’s Study Data
Company Announcements

Annovis Bio Shares Surge on Positive Parkinson’s Study Data

Pick the best stocks and maximize your portfolio:

Annovis Bio (ANVS) has provided an update.

Annovis Bio, Inc. has revealed exciting new data from its Phase III Parkinson’s study, capturing the attention of the stock market and financial observers. The announcement was made through a press release and the company has scheduled a detailed webcast discussion for the evening of July 2, 2024. Interested parties can find the registration details for this event on the company’s website under the Investors section.

For detailed information about ANVS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAnnovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials
TipRanks Auto-Generated NewsdeskAnnovis Bio Appoints William Fricker as Interim CFO
TheFlyAnnovis sees cash runway for Phase 3 preparatory studies, entering AD study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App